Global Cancer Biopsy Market Research Report to 2027 – Featuring Chronix Biomedical, Danaher, Epigenomics and Exact Sciences Among Others – ResearchAndMarkets.com

Global Cancer Biopsy Market Research Report to 2027 – Featuring Chronix Biomedical, Danaher, Epigenomics and Exact Sciences Among Others – ResearchAndMarkets.com




Global Cancer Biopsy Market Research Report to 2027 – Featuring Chronix Biomedical, Danaher, Epigenomics and Exact Sciences Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Biopsy Market Research Report by Type (Liquid Biopsies and Tissue Biopsies), Product, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.

The Global Cancer Biopsy Market size was estimated at USD 23.76 billion in 2021, USD 26.61 billion in 2022, and is projected to grow at a CAGR 12.17% to reach USD 47.35 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Biopsy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Biopsy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Biopsy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Biopsy Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Biopsy Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Biopsy Market?

6. What is the market share of the leading vendors in the Global Cancer Biopsy Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Biopsy Market?

Market Dynamics

Drivers

  • Increasing preference for non invasive procedures
  • Emerging significance of cancer biopsies and tissue sectioning
  • Growing adoption of liquid biopsies

Restraints

  • Low sensitivity and specificity

Opportunities

  • Series of advancements in image-guided biopsies
  • High growth potential in emerging markets

Challenges

  • Unclear regulatory and reimbursement scenarios

Companies Mentioned

  • ANGLE plc
  • BD (Becton, Dickinson and Company)
  • BIOCEPT, INC.
  • Biodesix (Integrated Diagnostics)
  • Chronix Biomedical, Inc.
  • Danaher
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Freenome Holdings, Inc.
  • Genesystems, Inc. (Genesys Biolabs)
  • GRAIL, Inc.
  • Guardant Health
  • HelioHealth (Laboratory for Advanced Medicine)
  • Hologic, Inc.
  • Illumina, Inc.
  • Lucence Diagnostics Pte. Ltd.
  • Myriad Genetics
  • Natera, Inc.
  • Oncimmune
  • Personal Genome Diagnostics Inc.
  • Personalis Inc.
  • QIAGEN
  • Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/e0g246

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900